UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

~~SECURITIES AND EXCHANGE COMMISSION~~ _________________

WASHINGTON, DC 20549

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~Securities~~Date ~~Exchange~~of ~~Act~~Report (Date of ~~1934~~earliest event reported): September 03, 2015

~~Date of Report: November 25, 2014~~_______________________________

(Date of earliest event reported)

Cortronix Biomedical Advancement Technologies, Inc.

(Exact name of registrant as specified in its charter)

Nevada	000-53700	98-0515701
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
8200 N.W. 41st Street, Suite 145B, Doral, FL		33166
(Address of principal executive offices)		(Zip Code)

_______________________________

(786) 859-3585

Nevada	000-53700	98-0515701
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

~~(Registrant’s~~8200 ~~telephone~~N.W. ~~number~~41st Street, ~~including~~Suite ~~area~~145B, ~~code)~~ Doral, FL 33166

(Address of Principal Executive Offices) (Zip Code)

(786) 859-3585
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨X Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~SECTION ~~3.03~~5 ~~Material~~- CORPORATE ~~Modification~~GOVERNANCE toAND ~~Rights of Security Holders.~~MANAGEMENT

~~The disclosures set forth in~~ Item 5.0302 Departure of ~~this~~Directors ~~current~~or ~~report~~Certain onOfficers; ~~Form~~Election ~~8-K~~of ~~are~~Directors; ~~incorporated~~Appointment byof ~~reference~~Certain ~~herein~~Officers; Compensatory Arrangements of Certain Officers.

~~Item~~Resignation ~~5.03 Amendments to Articles~~ of ~~Incorporation or Bylaws; Change in Fiscal Year.~~Officer(s)

OnEffective ~~November~~September 253, ~~2014~~2015, ~~Cortronix Biomedical Advancement Technologies, Inc~~Mr. ~~(the “Company”) effected a reverse stock split (the “Reverse Split”)~~Richard ofHull ~~all~~resigned ~~the~~as ~~authorized and outstanding shares of~~ the ~~Company’s common stock~~President, ~~$.001~~Chief ~~par~~Executive ~~value~~Officer, ~~per~~Chief ~~share~~Financial ~~(the “Common Stock”) at a ratio of one (1) share for every one hundred (100) shares outstanding~~Officer, soSecretary ~~that~~and ~~every~~Treasurer ~~one hundred (100) shares~~ of ~~Common~~Cortronix ~~Stock before the Reverse Split represents one (1) share of Common Stock after the Reverse Split. No fractional shares~~Biomedical ~~will~~Advancement ~~be issued~~Technologies, ~~and no cash or other consideration will be paid~~Inc. Instead, the Company will issue one whole share of the post-Reverse Split Common Stock to any shareholder who otherwise would have received a fractional share as a result of the Reverse Split. The Reverse Split becomes effective with FINRA (the ~~Financial Industry Regulatory Authority) and in the marketplace at the open of business on December 19, 2014 (the~~ “~~Effective Date~~Company”)~~, whereupon the shares of Common Stock will begin trading on a split-adjusted basis~~. On the Effective Date, the Company’s trading symbol will change to “CBATD” for a period of 20 business days, after which the “D” will be removed and the Company’s trading symbol will revert to the original symbol of “CBAT”. In connection with the Reverse Stock Split, the Company’s CUSIP number will change to 220801203.

According to the Company’s Certificate of Change filed pursuant to Nevada Revised Statutes §78.209 (the “Certificate of Change”) with the Nevada Secretary of State, the maximum number of shares of Common Stock that the Company is authorized to issue was reduced from 800,000,000 to 8,000,000, and the Common Stock’s par value remained the same. The Reverse Split was effected without obtaining shareholder approval pursuant to Nevada law.SIGNATURE

~~Immediately~~Pursuant ~~prior~~ to the ~~Reverse~~ ~~Split,~~requirements ~~the Company had approximately 349,500,000 shares~~ of ~~Common Stock outstanding. After~~ the ~~Reverse Split, the Company~~Securities ~~has~~Exchange ~~approximately~~Act ~~3,495,000~~of ~~shares outstanding. Each shareholder’s percentage ownership in the Company and proportional voting power remains unchanged after the Reverse Split~~1934, ~~except for minor changes and adjustments resulting from~~ the ~~rounding~~registrant ofhas ~~fractional interests.~~duly ~~The~~caused ~~rights~~this ~~and~~report ~~privileges~~to ofbe ~~the~~signed ~~holders~~on ofits ~~Common~~behalf ~~Stock are substantially unaffected~~ by the ~~Reverse~~undersigned ~~Split~~hereunto duly authorized.

~~Shareholders~~Cortronix ~~who~~Biomedical ~~are~~Advancement ~~holding their~~Technologies, ~~shares of Common Stock in electronic form at their brokerage firms do not have to take any action as the effects of the Reverse Split will automatically be reflected in their brokerage accounts~~Inc. ~~Shareholders~~By: ~~holding paper certificates may (but are not required to) send the certificates to the Company’~~/s/ ~~transfer~~Richard ~~agent~~Hull atName: ~~the~~Richard ~~address~~Hull ~~given~~Title: ~~below.~~Chief ~~The~~Executive ~~transfer~~Officer, ~~agent~~President, ~~will~~Secretary ~~issue~~and aTreasurer ~~new share~~and ~~certificate reflecting the terms of the Reverse Split to each requesting shareholder.~~Director

~~Action~~Date: ~~Stock~~September ~~Transfer Corporation 2469 E. Fort Union Blvd.~~3, ~~Suite 214 Salt Lake City, UT 84121~~2015

Telephone: (801) 274-1088 Fax: (801) 274-1099 Email: info@actionstocktransfer.com

Until surrender, each certificate representing shares of Common Stock before the Reverse Split would continue to be valid and would represent the adjusted number of shares of Common Stock based on the exchange ratio of the Reverse Split, rounded up to the nearest whole share. Shareholders should not destroy any stock certificate.

All options, warrants and convertible securities of the Company outstanding immediately prior to the Reverse Split will be appropriately adjusted by dividing the number of shares of Common Stock into which the options, warrants and convertible securities are exercisable or convertible by 100 and multiplying the exercise or conversion price thereof by 100, as a result of the Reverse Split.

A copy of the Certificate of Change is attached to this current report on Form 8-K as Exhibit 3.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
3.1		Certificate of Change pursuant to Nevada Revised Statutes § 78.209.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cortronix Biomedical Advancement Technologies, Inc. By: Richard A. Hull Name: Richard A. Hull Title: Chief Executive Officer

Dated: __Dec. 08_, 2014

Filing Compare · Cortronix Biomedical Advancement Technologies Inc.